About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Court Report | Main | G.D. Searle LLC v. Lupin Pharmaceuticals, Inc. (Fed. Cir. 2015) »

June 23, 2015

Comments

Michael,

Another sad instance of application of the broken Alice test for determining patent-eligibility. But what truly boggles my mind is that Newman has now apparently embraced this broken test. Why she did so (without any protest like Linn did in the Sequenom case) frankly leaves me scratching my head.

As EG notes, another sad instance (of an item that I can remind Paul Cole of "I told you so")...

Perhaps a better question: where will this end?

Yes, this opinion is surprising coming from Newman, as her Alice dissent / concurrence was the only part of the en banc opinion that made sense.

While we are bashing patent drafters let us not forget that clients are also to blame for pushing drafters to write maximally broad claims. If the law had been clear upfront then I’m sure patent applications would have been more detailed and patent claims would have been more focused.

Many of these recent decisions have told us what is not patentable. Is there anything that is before the Fed. Cir. or that is making its way to the Fed. Cir. that might tell us what is patentable?

What about the Planet Blue case? There was a lot of noise when those claims were rejected. Are the claims in that case pretty much dead in view of the recent decisions?

Following up on my previous post about Planet Blue.

I guess the question now is whether or not the steps of “generating an output morph weight set stream by applying said first set of rules to each sub-sequence of said plurality of sub-sequences of timed phonemes” and “applying said output morph weight set stream to an input sequence of animated characters to generate an output sequence of animated characters with lip and facial expression synchronized to said audio sequence” provide sufficient details of the method by which whatever was supposed to be accomplished by the claim is accomplished?

I have no idea how the Fed. Cir. plans to define the boundary (if indeed this is what they are planning to do) that separates valid software patents from invalid ones based on the level of algorithmic detail.

I suspect that Planet Blue will be decided on different grounds, namely whether the claimed invention goes beyond merely automating known human activity. We are writing a post on that case, as the plaintiff's brief is now available.

Thanks Mike - I look forward to the post.

I comment more on natural products because the result in that field are at variance with what happens in Europe, whereas in software/business methods the trend is to converge towards what happens in Europe.

In this particular case, the description is quite detailed so that the outcome is a little surprising. The invention appears to reside in the idea of providing improved functionality rather than its implementation, and EPO practice recognises invention in identifying the problem to be solved as well as in identifying the solution. Possibly the invention here is the implementation of a design choice which had not been implemented before, but which was nevertheless obvious to implement. If in Patent Docs you are half way through entering a comment and navigate away from the page, then your comment is lost, which can be very irritating, and a software implementation that does not suffer from that problem has obvious benefits.

A European view on Sequenom calls for a guest posting rather than a comment, and I am currently working on this.

if a mechanical-machine patent claimed "receiving a penny inserted by a user into a slot of a black box; imprinting an image of the user onto the penny and delivering the imprinted penny through another slot of the black box" without describing what's in the black box and how that is accomplished, you'd all protest that that is an invalid patent. yet, something is wrong with this absolutely correct decision? mind boggling, indeed. if such basic, fundamental requirements are "rich, detailed, technical specifications" well, good luck to ya!

Lets take a typical drug patent claim:

1) A method of treating X disease with a known drug.

Applying the rationale of court, "claim 1 contains no restriction on how the result is accomplished,", considering that it is a known drug and hence does not provide novelty and hence ignored like the court did, the claim does not include how Known Drug is treating X disease hence is not eligible too.

This logic makes majority, if not 90% of drug patents invalid as they don't tell you how the drug gives the specific effect in the body! Are we now supposed to include the biochemistry into the drug method claims? Are we going to have biochemists arguing in court which enzyme is responsible for the effect of the drug for patent eligibility?

@ Scientist

I think you will find postings of mine on Prometheus v Mayo making this very point. The example I used was nitroglycerin and a nitroglycerin composition for treatment of angina.

The rationale is that the effectiveness of nitroglycerin against angina is a rule of nature and the formulation into a pharmaceutically acceptable form is routine post-solution activity. However, you will also see a statement in the Prometheus opinion that there is no intention to disturb pharmaceutical patents generally and the opinion ends with a warning that it is fairly fact-specific and may not be general.

The conclusion I reached at the time (see postings and an article in the CIPA journal (copies on request) is that there is no workable rule of law derivable from the Prometheus opinion.

The difficulty in my submission is the taking of statements out of the whole context of the opinion and their application to factual situations and with a severity that was not intended. Not every Supreme Court case deals with fundamentals such as health care and there is a tendency to exaggerate ("gold plate" as we say in the UK) opinions and regulations which were originally intended to be narrow and specific.

Mr Cole, dare I remind you...?

@ Skeptical

I am well aware of your views, as you are of mine, and I need no reminding.

There is, unfortunately, no other furrow to plough since an amendment to 35 USC or a favourable case going to the Supreme Court is at best a medium-term event and does not affect the here and now.

Believe me, although it is interesting and educational there are many things I would rather do than prepare detailed comments on US opinions. But the US issues are existential for some of our clients and some members of our profession, and we owe it to ourselves and our colleagues to argue for a more moderate and reasoned approach both by the courts and by the USPTO.

There is, unfortunately, my paradigm decision interpreter who is a contributor to the New York Times with a degree in economics (and hence a detailed understanding neither of technology nor of law), who has become very active in the last few years, and who seems have wandered into law rather than mere journalism. If we can raise the level of understanding and interpretation we may be able to influence future cases in the right direction.

Mr.Cole,

The reason why I remind you is that your attempts at "more moderate and reasoned approaches" will fail - precisely because the approach you want to take is flawed.

To be perfectly blunt, your approach is too Pollyanna.

You want to act as if there are no other forces trying to bend patent law to different ends. You just won't succeed by ignoring the fact that others are occupying the attention span of those making the decisions on the front lines.

Trust me, I am ALL for your approach of reason and restraint, and I trust that my own level of understanding and interpretation of law and history are on at least a parallel with yours.

Sadly, that just wont be enough.

This is - and has been for a very long time - a soundbyte war, where the guerrilla tactics of propaganda and mindless repetition simply are more effective than the invitation to be thoughtful and exert careful mental effort.

It is NOT that I disagree with your goals, kind sir. Rather, I question the efficacy and sufficiency of merely inviting others to "think."

The reason why guerrilla tactics and propaganda are employed is because those things WORK. Perhaps some level of thought should be aimed at that, and not just at our understanding and respect of having a patent system.

You speak of duty and "owing," and I fully agree that there is a duty present. I wonder though if anyone agrees as to what that duty is when it comes to the different philosophies at play in shaping patent law.

@ Skeptical

I do not think we differ much.

Unfortunately the only weapons that I have are the weapons that I am using - detailed study and reasoned analysis, and these I intend to continue using with all the resources of time and energy that I can find for the task (I do also have other things to do).

I cannot join the sound byte war firstly because I do not have the knowledge and connections and secondly because that is not what I do. However, if a more reasonable approach is to be found it will be the result of the contributions of many people, and if what I am doing helps others in their task, that is more than enough.

Mr. Cole,

More than enough? Verily, that is simply not so.

One difference we do have: one of us embraces Pollyanna-ism and the other accepts the reality that there exists opposing forces that are perfectly willing to trounce "detailed study and reasoned analysis."

It is more than just a bit of hubris then to consider that what you do - as noble and correct as it may be in and of itself - as "more than enough" when (and as my words ring out: I told you so), they are clearly NOT enough.

I will recognize that you have limited bandwidth and have limited your choice of methodologies. That is your prerogative. However, to continue to post as if your choice will lead to the proper conclusions, and to embrace this sense of "more than enough" when it is so evident that it is not near enough is to knowingly fail. It is not a failure of attempt, but a failure of recognizing - and adapting - to what is necessary.

At the very least then, perhaps in addition to your words of wisdom (which status I can agree to), perhaps then you would add the simple caveat that more than just your view is needed to effect the aim of your view. Yes, your view is important, and yes (here), recognizing that it is one piece and that contributions by others (and contributions along the spectrum of response that I point out BEING one of those "others") is a step in the right direction, but all too often your writings do NOT exhibit this "enough-ness." All too often, your writings - as sound and as true as they are - merely are presented as being "enough." Bullets without guns, let alone bullets and guns without people with the fortitude to use them.

The comments to this entry are closed.

September 2024

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30